Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-009166
Filing Date
2021-05-06
Accepted
2021-05-06 07:10:32
Documents
78
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20210331.htm   iXBRL 10-Q 1439212
2 EX-10.5 amendedoptionagreement.htm EX-10.5 14523
3 EX-31.1 ex-311q12021.htm EX-31.1 9367
4 EX-31.2 ex-312q12021.htm EX-31.2 9348
5 EX-32.1 ex-321q12021.htm EX-32.1 7066
11 image_11.jpg GRAPHIC 6722
12 xfor-20210331_g1.jpg GRAPHIC 45229
  Complete submission text file 0001628280-21-009166.txt   6384544

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20210331.xsd EX-101.SCH 52108
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20210331_cal.xml EX-101.CAL 77974
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20210331_def.xml EX-101.DEF 196242
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20210331_lab.xml EX-101.LAB 566764
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20210331_pre.xml EX-101.PRE 361359
13 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20210331_htm.xml XML 900136
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 21895749
SIC: 2836 Biological Products, (No Diagnostic Substances)